Showing 20 of 173 recruiting trials for “squamous-cell-carcinoma-of-the-oropharynx”
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
👨⚕️ Matin Imanguli, JHU Sidney Kimmel Comprehensive Cancer Center LAO📍 3 sites📅 Started Aug 2026View details ↗
Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma
Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
👨⚕️ Lin Shen, Peking University Cancer Hospital & Institute📍 7 sites📅 Started Feb 2026View details ↗
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Hypofractionated Radiotherapy for Nasopharyngeal Carcinoma
👨⚕️ yuecan zeng, doctor, The Second Affiliated Hospital of Hainan Medical University📍 1 site📅 Started Feb 2026View details ↗
Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
👨⚕️ Jiang D Sui, Ph.D, M.D., Chongqing University Cancer Hospital📍 1 site📅 Started Feb 2026View details ↗
Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC
A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
RecruitingNCT07376603 ↗
IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk Features
Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)
👨⚕️ Xiaolong Yan, The Second Affiliated Hospital of Air Force Medical University📍 1 site📅 Started Dec 2025View details ↗
Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial
KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
RecruitingNCT07232680 ↗
Prospective Immuno-Radiomic Profiling in Nasopharyngeal Carcinoma Treated With Proton or Photon Chemoradiotherapy
👨⚕️ Rodney Cheng En Hsieh, MD, PhD, Chang Gung Memorial Hospital📍 1 site📅 Started Nov 2025View details ↗
40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma
👨⚕️ Zhihao MM Lu, PHD, Peking University Cancer Hospital & Institute📍 1 site📅 Started Nov 2025View details ↗
Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.
Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial
Page 1 of 9Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →